Cargando…
Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy
BACKGROUND: It has been recognized that primary membranous nephropathy (MN) is related to an increased risk for thromboembolic complications. However, the current evidence supporting prophylactic and therapeutic anticoagulation is too weak to better meet the clinical needs of this patient population...
Autores principales: | Zou, Honghong, Li, Yebei, Xu, Gaosi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889582/ https://www.ncbi.nlm.nih.gov/pubmed/31791286 http://dx.doi.org/10.1186/s12882-019-1637-y |
Ejemplares similares
-
Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019) -
Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
por: Li, Yebei, et al.
Publicado: (2021) -
Altered DNA methylation of TRIM13 in diabetic nephropathy suppresses mesangial collagen synthesis by promoting ubiquitination of CHOP
por: Li, Yebei, et al.
Publicado: (2020) -
Bioptically Proven “Anticoagulation-Related Nephropathy“ Induced by Dual Antiplatelet Therapy
por: Krátká, Karolína, et al.
Publicado: (2018) -
Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials
por: Yang, Pingping, et al.
Publicado: (2018)